

2025-2026 Respiratory Syncytial Virus (RSV) Prevention Programs

September 25, 2025

The 2025-2026 RSV Prevention Programs target the highest risk populations and settings. RSV season is generally between November 1st to March 31st, peaking in December. Administering RSV vaccines and monoclonal antibodies in the fall, as well as COVID-19 and flu vaccines, may:

- Provide protection to high-risk infants and older adults
- Protect individual health and the health of families and communities
- Protect and mitigate impacts on our health care system

RSV Product Administration

Administration of Beyfortus™ and Abrysvo® for the Infant and High-Risk Children RSV Prevention Program can begin on the program launch date, October 1, 2025.

There is no formal launch date for the Older Adult High-Risk RSV Vaccine Program; administration of Arexvy® or Abrysvo® to the older adult population may begin as soon as vaccine supply is available.

The RSV vaccine or monoclonal antibody can be co-administered with both seasonal and non-seasonal vaccines, including routine childhood vaccines. Co-administration is encouraged to help mitigate the impacts of the respiratory season.

Infant and High-Risk Children RSV Prevention Program

Ontario's publicly funded Infant and High-Risk Children RSV Prevention Program eligibility for the 2025-2026 RSV season will be as follows:

- All infants born after April 1, 2025 **and** less than eight months of age in their first RSV season and high-risk children up to 24 months of age in their second RSV season **who meet eligibility criteria** will have access to the Beyfortus™ monoclonal antibody
- Pregnant individuals from 32 to 36 weeks gestational age who will deliver near the start of or during the 2025-2026 season will have the option to receive the RSV vaccine Abrysvo®, which can help provide protection to infants from birth to six months of age
 - Note: Beyfortus™ is preferentially recommended over maternal vaccination with Abrysvo® by the National Advisory Committee on Immunization (NACI) due to its effectiveness, long-lasting protection and safety profile
 - Note: Administration of both Abrysvo® to the pregnant individual and Beyfortus™ to the infant is **not** recommended except under specific circumstances

For additional information on [RSV prevention for infants and high-risk children](#), refer to the attached Infant and High-Risk Children RSV Prevention Program Fact Sheet for Health Care Providers.

Older Adult High-Risk RSV Vaccine Program

Ontario's publicly funded Older Adult High-Risk RSV Vaccine Program eligibility for the 2025-2026 RSV season will be as follows:

- All individuals 75 years of age and older (**NEW for the 2025/2026 season**)
- Individuals 60 to 74 years of age **who are also**:
 - Residents of long-term care homes, Elder Care Lodges, or retirement homes including similar settings (e.g., co-located facilities)
 - Patients in hospital receiving alternate level of care (ALC) including similar settings (for example, complex continuing care, hospital transitional programs)
 - Patients with glomerulonephritis (GN) who are moderately to severely immunocompromised
 - Patients receiving hemodialysis or peritoneal dialysis
 - Recipients of solid organ or hematopoietic stem cell transplants
 - Individuals experiencing homelessness
 - Individuals who identify as First Nations, Inuit, or Métis

Eligible high-risk older adults 60 years of age and older are recommended to receive a single dose of either Arexvy® or Abrysvo® to help prevent RSV disease. If an individual has previously received a dose of RSV vaccine, they **do not** need to receive another dose this season, as booster doses are not currently recommended.

For additional information on [RSV prevention for high-risk older adults](#), refer to the attached Older Adult High-Risk RSV Vaccine Program Fact Sheet for Health Care Providers.

Ordering RSV Products

To order RSV products complete the attached 2025-2026 RSV Product Order Form and submit it by email to vaccineinventory@york.ca or by fax to 905-830-0578. A vaccine refrigeration unit temperature log with a minimum of the most current five (5) business days of temperature recordings must be submitted with each vaccine order form.

Contact Us

If you have any questions about the 2025-2026 RSV Prevention Programs or product distribution, storage and handling requirements, please contact the Vaccine inventory Program, at 1-877-464-9675 ext. 74033 or email vaccineinventory@york.ca.

Subscribe to York Region Public Health Matters

Public Health Matters is York Region Public Health's e-update to health care professionals. It includes important updates, opportunities to engage with us and resources you can use in your practice. It highlights programs offered by Public Health that are important to you and for your patients. While we know your inboxes are always full, Public Health Matters will be an invaluable way of staying connected to YRPH now and in the future.

Please [subscribe](#) today!